Estrogenic treatment in post-menopausal osteoporosis-Consensus of SMNE

2006, Number 3

Rev Endocrinol Nutr 2006; 14 (3)

Reza A

Language: Spanish
References: 7
Page: 182-184
PDF size: 60.28 Kb.

Text Extraction

No abstract

REFERENCES

Lindsay R, et al. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002; 287: 2668-76.
Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D, for the HERS Research Group: Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002; 288: 58-66.
Writing Group for the Womens´s Health Initiative Investigators. Risk and benefits of estrogens plus progestin in healthy postmenopausal women: principal results from the Womens´s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
The Womens´s Health Initative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women´s Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12.
Lindsay R, et al. Bone response to termination of estrogen treatment. Lancet 1978; 7: 1325-7.
Lufkin EG, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;114: 1-9.
Hsia JH, et al. Conjugated equine estrogens and coronary heart disease: The Women’s Health Initiative. Arch Intern Med 2006; 166: 357-365.